Fertility Drug Surgery Market Analysis

Global Fertility Drug and Surgery Market Overview

The Fertility Drug Surgery Market Size was valued at USD 2.03 Billion in 2023. The Global Fertility Drug Surgery industry is projected to grow from USD 2.19 Billion in 2024 to USD 3.81 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.33% during the forecast period (2024 - 2032).

Infertility is a reproductive problem in which the patient could not conceive the baby. Infertility may cause due to the problem in the reproductive system of either partner. There are various treatment & diagnosis methods to cure this problem for both male and female patient.  There are various symptoms faced by infertile men and woman. In a woman, it could be irregular menstrual periods, hormone fluctuation, and in men, it can be semen abnormalities, pelvic infections or sexually transmitted diseases and others.

 The key factors responsible for driving the market growth are an increase in infertility rates, increasing obesity, delayed pregnancies in women, increase in gamete donations, increase in disposable income, also rising healthcare expenditure worldwide is promoting the market growth.

The NIH...Turning Discovery into Health 2018 publication reported that around 11% of women and 9% of men of reproductive age in the US had experienced fertility problems. The increasing cases of infertility due to a sedentary lifestyle and other factors may boost the demand for fertility treatment and drive the market growth. However, the factors such as high cost of treatment, complications related to treatments and low awareness among the population may boost the market growth during the forecast period.

Major Key Players

Some of the key players are Eli Lilly, Baxter Healthcare Corporation, Ferring Pharmaceuticals, Inc., Merck & Co. Pharmaceutical Company, Noven Pharmaceuticalorganon, Inc., Janssen Pharmaceuticals Inc., Personal Products Company, Pfizer, Inc., Procter & Gamble Pharmaceuticals, Emd Serono, Inc., and others.

Intended Audience

• Fertility Clinics


• Government and private laboratories


• Research and Development (R&D) companies


• Medical research laboratories


• Market research and consulting service providers

Market Segmentation

The fertility drug and surgery market is segmented on the basis of underlying cause, drug, procedures, end user, and region.

On the basis of the underlying cause, the fertility drug and surgery market is segmented into male and female. By drug, the fertility drug and surgery market is categorized into clomiphene citrate, letrozole, Serophene, hormone treatment, gonadotrophins

aromatase inhibitors, estrogen receptor modulators, dopamine agonists, metformin hydrochloride and others. On the basis of procedures, the fertility drug and surgery market is segmented into hysteroscopy, laparoscopy and robotic laparoscopy, laparotomy/open surgery, egg retrieval, varicocelectomy, vasectomy reversal (vasovasostomy or vasoepididymostomy), sperm retrieval (epididymal aspiration). By end-user, the fertility drug and surgery market is categorized into fertility clinics, hospitals, clinical research institutes, and others.

Regional Market Summary

The Americas dominates the market for fertility drug and surgery owing growing number of infertile couples, delayed pregnancies in the female, growing obesity and increase in disposable income. Also, the adoption of a sedentary lifestyle leads to cause infertility problem among a large number of populations. According to the World Health Organization (WHO), in 2016, 39% of adults aged 18 years and above, i.e., approximately 39% of men and 40% of women were overweight. Additionally, as per the data mentioned by the Heart Foundation, during 2014 to 2015, approximately 28% of all Australian males aged 18 and over were obese, and about 27% of all Australian females aged 18 and over were obese. The increasing obesity among the population may boost market growth in this region.

In 2017, it was estimated that Europe stood second in the fertility drug and surgery market.

It is reported that the rising prevalence of sexually transmitted disease contributes to increasing infertility cases. According to the World Health Organization every year more than 340 million new cases of protozoal infections and sexually transmitted bacterial (STD) across the world. Thus, the increasing reported cases for STD drives the market growth within the region.

Asia-Pacific was the fastest growing region for the fertility drug and surgery market in 2017. Factors such as increasing awareness for women health, growing healthcare industries and development of various treatment methods for infertility drives the market in this region.

On the other hand, the Middle East and Africa holds the least share in the fertility drug and surgery market. The presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare for healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.

Research Methodology

Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.

• Primary Research

Extensive primary research was conducted to gain a deeper insight into the market and industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.

• Secondary Research

Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company web sites, an international organization of chemical manufacturers, some paid databases, and many others.

Market Segmentation

Fertility Drug and Surgery Market, by Underlying cause

• Male


• Female

Fertility Drug and Surgery Market, by Drug

• Clomiphene Citrate


• Letrozole


• Serophene


• Hormone Treatment


• Gonadotrophins


• Aromatase Inhibitors


• Estrogen Receptor Modulators


• Dopamine Agonists


• Metformin Hydrochloride


• Others

Fertility Drug and Surgery Market, by Procedures

• Hysteroscopy


• Laparoscopy and Robotic Laparoscopy


• Laparotomy/Open Surgery


• Egg Retrieval


• Varicocelectomy


• Vasectomy Reversal


• Sperm Retrieval

Fertility Drug and Surgery Market, by End-User

• Fertility Clinics


• Hospitals


• Clinical Research Institutes


• Others